Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
详细信息 查看全文
- 作者：Yuan-Chi Shen ; Po-Hui Chiang ; cphtem@yahoo.com.tw" class="auth_mail" title="E-mail the corresponding author ; Hao-Lun Luo ; Yao-Chi Chuang ; Yen-Ta Chen ; Chih-Hsiung Kang ; Chun-Chien Hsu ; Wei-Ching Lee ; Yuan-Tso Cheng
- 关键词：Chemotherapy ; Docetaxel ; Flare-up phenomenon ; Metastatic castration resistant prostate cancer
- 刊名：The Kaohsiung Journal of Medical Sciences
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：32
- 期：9
- 页码：458-463
- 全文大小：379 K
文摘
To determine the optimal number of cycles of docetaxel for metastatic castration-resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival, prostate-specific antigen (PSA) response, and adverse events. The study included 33 patients receiving ≤ 10 cycles of docetaxel and 40 patients receiving > 10 cycles. Patients receiving > 10 cycles were younger than those who received ≤ 10 cycles. There was no statistical significant difference in overall survival between the two groups (log-rank test, p = 0.75). Adverse effects were more common among patients receiving ≥ 10 cycles of treatment. A PSA flare-up was observed among six patients (8.2%); the median duration of the PSA surge was 3 weeks (range, 3–12 weeks). The overall survival rates in patients with PSA flare-up were comparable with the patients having PSA response. We concluded that at least four cycles of docetaxel should be administered in metastatic castration-resistant prostate cancer patients in order not to cease treatment prematurely from potentially beneficial chemotherapy. However, administering > 10 cycles does not result in any further improvement in survival and is associated with more adverse effects.